Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma

Inclusion Criteria: * 18 to 65 years of age. * Hemangioma with a diameter of 5-10 cm, no clinical symptoms, no obvious risk of hemangioma rupture and bleeding, no obvious symptoms of tumor compression, and excluding malignant diseases; or hemangioma without surgical indications but have a strong willingness to treat; compliance with treatment indications, but refuse surgical, interventional or radiotherapy radiative interventions. * No other beta receptor modulators (activation or blockade of beta receptor signaling) were given during the previous six months. * Eastern Cooperative Oncology Group score 0-2 points. Exclusion Criteria: * Liver lesions with other malignant tumors or hepatic hemangiomas are not clearly diagnosed or have other undefined features. * Hepatic hemangioma requires surgical or radiological intervention within a limited period of time, otherwise there may be a greater risk. * Beta receptor modulator therapy is required for cardiovascular and other diseases within six months. * Previous cardiovascular or cerebrovascular events or with high risk of cardiovascular and cerebrovascular events. * Suffering from severe liver diseases such as severe cirrhosis, hepatic adenoma, liver dysfunction and so on. * Post liver transplantation. * Heart rate \< 60 beats/min, blood pressure \< 100/60 mmHg, orthostatic hypotension, cardiac insufficiency or severe cardiovascular disease (moderate to severe hypertension, coronary atherosclerotic heart disease, severe or acut…